@inproceedings{inproceedings, title  = {{tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2014}},

 month = {{5}},

 author = {{Yardley DA and Brufsky A and Coleman RE and Conte PF and Cortes J and Glück S and Nabholtz J-MA and O'Shaughnessy J and Li L and Barton D and Beck RM et al}},

 doi = {{10.1200/jco.2014.32.15_suppl.tps1146}},

 volume = {{32}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{TPS1146-TPS1146}},

 note = {{Accessed on 2025/10/10}}}